Natixis’s Checkpoint Therapeutics CKPT Stock Holding History

Natixis’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,500	Closed	-$40K	–	1079
2020 Q4	$40K	Buy	+1,500	New	+$38K	﹤0.01%	1031

Other funds holding CKPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAG

Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Natixis's CKPT Position: Q1 2021 in Review

Natixis sold out of Checkpoint Therapeutics (CKPT) in Q1 2021, closing a stake of 1,500 shares — an estimated $40K sold.

Natixis first reported a position in CKPT in Q4 2020 and held it in 1 quarter. The position peaked at $40K in Q4 2020. 70 funds tracked by Wall St. Rank hold CKPT as of Q1 2021.

Natixis reported no remaining Checkpoint Therapeutics position as of Q1 2021 after selling out during the quarter.
Natixis sold 1,500 Checkpoint Therapeutics shares in Q1 2021, an estimated $40K.
Natixis first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 1 quarter.
Natixis's Checkpoint Therapeutics position peaked at $40K in Q4 2020.
70 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2021.

Based on Natixis's 13F filing for Q1 2021, filed 14 May 2021.